-
A Study of DLX105-DMP in Patients With Plaque Psoriasis
A Pilot, Open-Label, Two-Part Study in Subjects with Mild to Moderate Plaque Psoriasis to Investigate the Dosing Feasibility, Safety, and Local Tolerability of a Single Dose of DLX105-DMP Administered to a Target Lesion and the Safety, Local Tolerability, and Preliminary Efficacy of a Four-Week Multidose Regimen of DLX105-DMP Administered to a Target Lesion
-
A Study of EDP1815 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis
Evelo will investigate the safety and tolerability of EDP1815 and its potential to be a medicinal product in healthy volunteers and individuals with mild to moderate psoriasis and atopic dermatitis.
-
A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis
The purpose of this study is to assess the safety of subcutaneous (SC) golimumab in participants with active Ankylosing Spondylitis (AS) or Psoriatic Arthritis (PsA) over 24 weeks.
-
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
The purpose of this study is to evaluate the efficacy of guselkumab for the treatment of palmoplantar psoriasis.
-
A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis
The reason for this study is to see if the study drug ixekizumab is safe and effective in participants with generalized pustular psoriasis and erythrodermic psoriasis.
-
A Study of KHK4827 in Subjects With Palmoplantar Pustulosis
Evaluation of efficacy and safety of KHK4827 in Subjects with Palmoplantar Pustulosis
-
A Study of LY3471851 in Participants With Psoriasis
The main purpose of this study is to learn more about the safety and side effects of LY3471851 when given by injection just under the skin to participants with psoriasis. The study will last up to 48 weeks and may include up to 23 visits to the study center.
-
A Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice
This is a retrospective, multi-center observational cohort study. This study will be implemented first in Germany (approximately 50 sites), the United Kingdom (approximately 20 sites) and Sweden (approximately 25 sites), followed by a selected number of countries in Europe, depending on apremilast local availability. The design of this apremilast retrospective study aims to provide clinical information regarding the treatment initiation and outcomes in psoriasis patients when prescribed apremilast in real world settings. In addition, this study is aiming at capturing physicians' and patients' treatment goals when initiating apremilast and...
-
A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)
The aim of this study is to assess the therapeutic efficacy of secukinumab on the psoriatic skin and to explore the anti-inflammatory (reduction of hepatic inflammation and cell damage), anti-steatotic (reduction of hepatic triglyceride content) and anti-fibrotic (reduction of hepatic fibrosis) effects of secukinumab in patients with psoriasis and coexisting non-alcoholic fatty liver disease (NAFLD).
-
A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Subjects With Manifestations of Plaque Psoriasis and Impaired Quality of Life
This is a Phase 4, multi-center, randomized, placebo-controlled, double-blind study of the impact of apremilast on quality of life, efficacy, and safety in subjects with manifestations of plaque psoriasis and impaired quality of life. Approximately 255 subjects will be randomized 2 (apremilast):1 (placebo) in approximately 6 to 10 countries in Western Europe. Subjects will be block-randomized equally to each of the manifestations of psoriasis (scalp psoriasis, nail psoriasis, palmoplantar psoriasis, genital psoriasis, and psoriasis in visible locations). If subjects present with multiple manifestations, they will be allocated to the...
51 - 60 of 272 Trials
- Psoriasis
-
- Psoriatic Arthritis
-
- Psoriatic Disease
- Stay Healthy
-
Community
- icon:
Navigation CenterLink text:Get free, personalized guidance and support for psoriasis and psoriatic arthritis. - icon:
Talk PsoriasisLink text:The world’s online support community for those impacted by psoriasis or psoriatic arthritis. - icon:
One to OneLink text:Are you newly diagnosed? Have questions? Connect with someone who’s been through it. - icon:
Our SpotLink text:A new website for parents, kids and teens with psoriasis and psoriatic arthritis!
Stay Informed
- icon:
Health WebcastsLink text:Hear world-class experts provide the latest information on psoriatic disease.
-
- Get Involved
-
- Events and Programs
- icon:
Team NPFLink text:Join a group of everyday people dealing with psoriatic disease by walking, running, cycling and DIY-ing for a cure. - icon:
More than Skin DeepLink text:Outsmart psoriasis and psoriatic arthritis from the inside out at this local event.
-
- Research
-
- NPF Funded Research
- icon:
Victor Henschel BiobankLink text:A collection of biological samples and clinical information used by qualified scientists to advance the field of psoriasis genetics.
-
- Medical Professionals
-
- Stay Up-to-date
- icon:
Journal of Psoriasis and Psoriatic ArthritisLink text:Dedicated to providing practical information and research to those working in psoriatic disease care. - icon:
Continuing EducationLink text:Please join us at one of our educational events designed for health care providers.
-
